Successful placement of shares with a strategic investor in the healthcare industry to accelerate market entry in Europe
|
EQS-News: Viromed Medical AG
/ Key word(s): Miscellaneous
Viromed Medical AG: Successful placement of shares with a strategic investor in the healthcare industry to accelerate market entry in Europe Pinneberg, 5 February 2025 –Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) was informed by its majority shareholder (together with his wife) and CEO Uwe Perbandt about the off-market placement of a total of 1,250,000 shares from his holdings. In a private placement, shares totaling around 6.17% of the company's share capital were sold to a strategic investor in the healthcare industry. Uwe Perbandt and his wife remain the majority shareholders of the company and will continue to fully support the future development of Viromed Medical AG. Uwe Perbandt, CEO of Viromed Medical AG, explains: “The reallocation of some of my shares is a positive development for Viromed Medical AG. The increasing engagement of leading medical companies and investors confirms the promising perspectives of Viromed. In addition, we will benefit from the profound expertise and extensive network of our new investor in order to accelerate the company's entry into the European market in a targeted manner. This secondary placement is therefore in the best interest of all shareholders and the company as a whole.”
About Viromed Medical AG: Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region. Viromed Medical AG is pursuing the goal of further advancing the use of CAP in medicine in the coming years and realizing the corresponding growth potential.
Contact Viromed Medical AG Uwe Perbandt
05.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Viromed Medical AG |
| Flensburger Straße 18 | |
| 25421 Pinneberg | |
| Germany | |
| Phone: | +49 4101 809960 |
| E-mail: | kontakt@viromed-medical.de |
| Internet: | https://www.viromed-medical-ag.de/ |
| ISIN: | DE000A3MQR65 |
| WKN: | A3MQR6 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf (Primärmarkt), Frankfurt (Basic Board), Hamburg |
| EQS News ID: | 2081235 |
| End of News | EQS News Service |
|
|
2081235 05.02.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.